GlaxoSmithKline (CAI:BIOC) Research & Development: E£0 Mil (TTM As of Sep. 2016)


What is GlaxoSmithKline Research & Development?

GlaxoSmithKline CAI:BIOC +1.17% Research & Development is E£0 Mil as of Sep. 2016.

Research & Development is the aggregate amount of research and development expenses during the year. GlaxoSmithKline's Research & Development for the three months ended in Sep. 2016 was E£0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2016 was E£0 Mil.

GlaxoSmithKline  (CAI:BIOC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

GlaxoSmithKline Research & Development Related Terms

GlaxoSmithKline Research & Development Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Research & Development Chart

GlaxoSmithKline Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Research & Development
0.00 0.00 0.00 0.00

GlaxoSmithKline Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GlaxoSmithKline Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was E£0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of E£0 Mil mean?
GlaxoSmithKline (CAI:BIOC) has a Research & Development of E£0 Mil as of Sep. 2016. Research and development expense is the total cost for research and development activities. View historical data on GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's Research & Development too high?
GlaxoSmithKline's current Research & Development is E£0 Mil.
How does GlaxoSmithKline's Research & Development compare to PRPH?
GlaxoSmithKline's Research & Development of E£0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on GlaxoSmithKline and its competitors. GlaxoSmithKline's current Research & Development is E£0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Research & Development of E£0 Mil. The current Research & Development is E£0 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Research & Development is E£0 Mil as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlaxoSmithKline Business Description

Address Boomerang Building, No 46, Block (J) First Section City Centre, Town Centre, Second floor, Fifth District - New Cairo, Cairo, EGY, 11835
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.